Compare Paycom Software Inc (PAYC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Paycom Software Inc trades at $239.95 (market cap $10.77B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Paycom Software Inc is far larger — about 2.1× Travere Therapeutics Inc. Common Stock's market cap, and Paycom Software Inc pays a 0.63% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PAYC | TVTX | |
|---|---|---|
Market Cap | $10.77B | $5.02B |
Volume | 536,440 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $240.52 | $67.52 |
52-Week Low | $113.59 | $26.79 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $11.56B | $5.15B |
Dividend Yield | 0.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $236.60, up 0.68% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 22.78% net margins and consistent earnings beats, including Q2 2026 EPS of $2.78 beating expectations by 17%. Recent institutional buying and positive analyst coverage support the stock's upward trajectory despite RSI indicators suggesting potential overbought conditions.
PAYC presents growth potential with accelerating profitability and raised 2026 guidance, though current price exceeds analyst consensus target. Key risks include competitive pressures in payroll software and market volatility. The stock's premium valuation requires sustained execution to justify further upside from current levels near resistance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
